血清 SYPL1 是结直肠癌有前途的诊断生物标志物。
Serum SYPL1 is a promising diagnostic biomarker for colorectal cancer.
机构信息
Medical Research Center, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, The Second Chengdu Hospital Affiliated to Chongqing Medical University, Chengdu, Sichuan 610031, China.
Department of Clinical Laboratory, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610031, China.
出版信息
Clin Chim Acta. 2020 Oct;509:36-42. doi: 10.1016/j.cca.2020.05.048. Epub 2020 Jun 2.
BACKGROUND
At present, the overall sensitivity and specificity of blood biomarkers are insufficient for a diagnosis of colorectal cancer (CRC).
METHODS
We analyzed the serum synaptophysin like 1 (sSYPL1) in controls, adenoma patients, CRC patients, pre- and postoperative CRC patients by ELISA.
RESULTS
The upregulation of SYPL1 was confirmed in CRC tissues at both mRNA and protein levels. Consistently, sSYPL1 was significantly higher in CRC patients than in either controls (t = 14.50, P < 0.0001) or adenoma patients (t = 10.56, P < 0.0001) and was associated with lymph node invasion (χ = 4.27, P = 0.039). ROC curves showed that sSYPL1 performed superbly in distinguishing CRC patients from controls (AUC: 0.9481; sensitivity: 86.09%, specificity: 91.01%) and adenoma (AUC: 0.8631; sensitivity: 98.68%, specificity: 78.08%). This performance was much better than that of carcinoembryonic antigen (CEA) or carbohydrate antigen 19-9 (CA19-9). Even for patients with low CEA levels (under 5 ng/mL), SYPL1 maintained the same high performance for identification of CRC. Furthermore, sSYPL1 levels declined significantly after radical surgery (t = 5.903, P < 0.0001).
CONCLUSION
sSYPL1 might be an outstanding marker for CRC diagnosis, especially for patients with low CEA levels.
背景
目前，血液生物标志物的整体敏感性和特异性不足以用于结直肠癌（CRC）的诊断。
方法
我们通过 ELISA 分析了对照组、腺瘤患者、CRC 患者、CRC 患者术前和术后的血清突触素样蛋白 1（sSYPL1）。
结果
CRC 组织中 SYPL1 的表达在 mRNA 和蛋白水平均上调。同样，CRC 患者的 sSYPL1 显著高于对照组（t=14.50，P<0.0001）或腺瘤患者（t=10.56，P<0.0001），并与淋巴结侵犯有关（χ=4.27，P=0.039）。ROC 曲线显示，sSYPL1 区分 CRC 患者与对照组（AUC：0.9481；灵敏度：86.09%，特异性：91.01%）和腺瘤（AUC：0.8631；灵敏度：98.68%，特异性：78.08%）的性能非常出色。这种性能明显优于癌胚抗原（CEA）或糖类抗原 19-9（CA19-9）。即使对于 CEA 水平较低（低于 5ng/mL）的患者，SYPL1 仍保持识别 CRC 的相同高性能。此外，sSYPL1 水平在根治性手术后显著下降（t=5.903，P<0.0001）。
结论
sSYPL1 可能是 CRC 诊断的一个出色标志物，尤其是对于 CEA 水平较低的患者。
Zotero 插件